About Inhalon

Inhalon Biopharma is a clinical-stage biotechnology company developing revolutionary inhaled antibody treatments for acute respiratory infections.

Inhalon is rapidly advancing programs for the treatment of multiple respiratory infections:

Respiratory Syncytial Virus
Influenza
Human metapneumovirus
SARS-CoV-2

Because preventative vaccine therapies for acute respiratory infections fail to fully protect people from infection, Inhalon’s breakthrough technology has the potential to address a massive unmet need by treating active infection, directly in the lung.

And, Inhalon's solution is designed to do even more.

History

2018

Inhalon Biopharma founded by Sam Lai, Ph.D.

2019

Received $500,000 from The Thiel Foundation through Breakout Labs
Appointed John Whelan as Chief Executive Officer

2020

Raised $3.1Million in Series Seed led by Life Science Angels

2021

Awarded $7 Million grant from U.S. Army Medical Research & Development Command (USAMRDC) to study IN-006, an Inhaled "Muco-trapping" Antibody for the Treatment of COVID-19
Appointed Jeff Hutchins, Ph.D. as Chief Development Officer
Dosed first patient in Phase 1 Study of inhaled IN-006

2022

Completed Phase 1 study of inhaled IN-006
Raised $5 Million in Series A led by JSR Life Sciences and Life Science Angels
Awarded $2 Million grant from National Institutes of Health (NIH) for IND-enabling development of inhaled IN-002, a potential treatment for respiratory syncytial virus (RSV)
Released data for the Phase 1 inhaled IN-006 study on medRxiv
Awarded $1.7 Million grant from the North Carolina Collaboratory at University of North Carolina at Chapel Hill to Develop IN-007, an Inhaled ACE2-Targeting Therapeutic for SARS-CoV-2

2023

Dosed first patient in Phase 1b Study of inhaled IN-006
Awarded $1 Million from NIH to support IN-002 for RSV
Awarded $6 Million grant from U.S. Army Medical Research & Development Command (USAMRDC) to study IN-007, an Inhaled ACE2-Targeting Therapeutic for SARS-CoV-2